Abbott India Limited (ABBOTINDIA.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹25,488.50 (+1.06%) as of
Key statistics
- Market cap
- 541.61B
- P/E (TTM)
- 35.87
- Forward P/E
- 30.97
- EPS (TTM)
- 710.49
- Dividend yield
- 1.75%
- 52-week range
- 25,227.40 – 35,921.55
- Beta
- -0.00
- Revenue (TTM)
- 67.14B
- Profit margin
- 22.47%
- Analyst target
- ₹34,723.75
- Volume
- 167.00
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 3,659
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.